Cagrilintide — 10 mg

Cagrilintide is a long-acting synthetic amylin analog developed as a non-selective agonist at the amylin and calcitonin receptor family. The peptide is structurally derived from native human amylin with multiple amino acid substitutions to enhance stability and reduce aggregation, and a C20 fatty diacid moiety conjugated via a γGlu-(AEEA)₂ linker enabling reversible albumin binding and an extended pharmacokinetic profile compatible with once-weekly subcutaneous dosing. In published preclinical and clinical research, cagrilintide is investigated as a satiety-pathway compound that complements GLP-1 receptor activation, with research interest in food intake regulation, body composition, gastric emptying, and metabolic endpoints. It is studied both as a single-agent compound and as a fixed-ratio combination partner with semaglutide (CagriSema) in the broader incretin / amylin research category.

Benefits (Research Focus)

• Amylin receptor agonism — studied for activation of the amylin and calcitonin receptor family

• Satiety pathway research — investigated for food intake reduction and appetite regulation endpoints

• Body composition — examined for fat-mass and lean-mass partitioning in DIO and obesity models

• Gastric emptying — explored for delayed gastric transit and downstream satiety effects

• Long-acting profile — C20 fatty diacid albumin-binding chemistry for extended half-life consistent with once-weekly research dosing

What Researchers Look At

• Amylin receptor (AMY1R / AMY3R) and calcitonin receptor (CTR) binding affinity

• cAMP activation curves in cell lines expressing amylin receptor subtypes

• Food intake, body weight, and adipose-tissue change in DIO rodent models

• Combination pharmacology with GLP-1 agonists (e.g., CagriSema research)

• Comparative endpoints versus eloralintide, pramlintide, and other amylin analogs

Quick Specs

• Form: Lyophilized white powder

• Net Peptide Content: 10 mg per vial

• Quantity: 1 vial

• Appearance: White to off-white lyophilizate

• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)

• Purity: ≥99% by HPLC

• Identity: MS-verified (per COA)

• Storage: Protect from light

Identity Basics

• Compound: Cagrilintide

• Synonyms: AM833; NNC0174-0833

• Class: Long-acting amylin analog; non-selective amylin / calcitonin receptor agonist (32 amino acids)

• Modification: Lipidated with C20 fatty diacid via γGlu-(AEEA)₂ linker on Lys residue; intramolecular disulfide bridge between Cys²–Cys⁷; multiple substitutions for stability and reduced aggregation

• Formula / M.W.: C₁₇₄H₂₈₈N₄₈O₅₅, ~3789.45 g/mol

• CAS: 1415456-99-3

⚠️ Disclaimer

• This product is intended for laboratory research use only.
• Not for human or veterinary use.
• Not approved for diagnostic, therapeutic, or medical applications.
• Handle using appropriate laboratory safety procedures and personal protective equipment.

COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.

Janoshik COA — Third-Party Testing